top of page
Executive Spotlights

Bioventus Inc. Names Robert Claypoole as President and CEO, Effective January 10, 2024, Succeeding Interim CEO Anthony Bihl

Durham, NC, December 19, 2023 (Globe Newswire) -- Bioventus Inc. (Nasdaq: BVS), a renowned global leader in cutting-edge solutions for active healing, announced today that its Board of Directors has designated Robert (Rob) Claypoole as the President and Chief Executive Officer of Bioventus, and he will also assume a role as a member of the Board of Directors. This appointment is slated to take effect on January 10, 2024. Mr. Claypoole will succeed Mr. Anthony Bihl, who has served as interim CEO and a director on the Board since April 2023.


Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma

Comments


Life Science Headlines
bottom of page